Kona Medical Announces Initiation of WAVE I Study of Renal Denervation Therapy for Hypertension
10/23/2012 9:09:03 AM
BELLEVUE, Wash. & MENLO PARK, Calif.--(BUSINESS WIRE)--Kona Medical, Inc. (www.konamedical.com) today announced the initiation of the first clinical study of its device therapy for drug-resistant hypertension. The Kona Surround SoundTM system utilizes focused ultrasound, delivered from outside the body, to treat the nerves leading to and from the kidney. The therapy of renal denervation has been shown in other studies to lead to significant and lasting reductions in high blood pressure. Kona is sponsoring the WAVE I clinical study to evaluate the safety and efficacy of its novel technology. WAVE I is now enrolling subjects at St. Vincent’s Hospital in Melbourne, Australia, under the direction of Primary Investigator Robert Whitbourn, MD. The study design and initial results of WAVE I will be presented on behalf of the investigators by Todd Brinton, MD on Wednesday, October 24th at the Transcatheter Cardiovascular Therapeutics conference in Miami, Florida.
comments powered by